Playlist

Kyrgyz Prime Minister Arrives in Ashgabat for High-Level CIS Summit

22 May. 04:00

Source

The Chairman of the Cabinet of Ministers and Head of the Presidential Administration of the Kyrgyz Republic, Adylbek Kasymaliyev, has arrived in Ashgabat on an official working visit. The high-ranking dignitary and his accompanying delegation were formally received by state officials at the Ashgabat International Airport. This visit reflects the ongoing diplomatic engagement and strong bilateral ties between the two Central Asian nations.

The primary objective of the Kyrgyz Prime Minister’s visit is to participate in the upcoming session of the Council of Heads of Government of the Commonwealth of Independent States (CIS), scheduled to take place in the Turkmen capital on May 22. This major regional forum brings together top executive officials from member states to coordinate policy and foster multilateral integration across the region.

The agenda for the upcoming ministerial-level assembly covers a broad spectrum of strategic cooperation sectors. Delegates will focus heavily on expanding trade and economic partnerships, optimizing regional supply chains, and deepening cultural and humanitarian exchanges between the participating countries. Joint efforts to address regional socioeconomic stability will also be a major point of discussion.

In addition to attending the main plenary sessions of the CIS Council, Prime Minister Kasymaliyev is expected to engage in several high-level bilateral meetings on the sidelines of the summit. These separate discussions will allow the Kyrgyz leadership to negotiate specific mutual agreements with Turkmenistan and other regional counterparts, focusing on trade, energy, and logistics cooperation.

‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌

Simple Vitamin Shows Surprising Results in Pre-Cancerous Blood Conditions, Study Finds

Today in 02:02

Source

Daily high-dose supplementation of vitamin C can significantly reduce mortality risks and help prevent severe medical complications in patients with pre-cancerous blood conditions. Researchers from the Van Andel Institute in the United States and Copenhagen University Hospital in Denmark reached this conclusion following a comprehensive three-year follow-up study. The international "EVITA" trial involved volunteers who were administered 1,000 mg of vitamin C daily over the course of a year, while a control group received a placebo.

Although initial hypotheses suggested vitamin C might directly inhibit abnormal cell proliferation, researchers found its primary benefit lay in strengthening the body, reducing systemic inflammation, and lowering rates of anemia, pneumonia, and internal bleeding. Over the three-year observation period, the vitamin C group exhibited a significantly higher survival rate compared to the placebo group. While experts emphasize that these findings remain preliminary and require larger clinical trials before reshaping formal medical treatment protocols, vitamin C continues to show promising potential in supportive patient care.

‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌
‌